100 related articles for article (PubMed ID: 30277666)
21. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma.
Chakravarty D; Srinivasan R; Ghosh S; Gopalan S; Rajwanshi A; Majumdar S
Int J Gynecol Cancer; 2007; 17(4):905-13. PubMed ID: 17309672
[TBL] [Abstract][Full Text] [Related]
23. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
[TBL] [Abstract][Full Text] [Related]
24. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
[TBL] [Abstract][Full Text] [Related]
25. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study.
Rossi L; Le Frere-Belda MA; Laurent-Puig P; Buecher B; De Pauw A; Stoppa-Lyonnet D; Canlorbe G; Caron O; Borghese B; Colas C; Delhomelle H; Chabbert-Buffet N; Grandjouan S; Lecuru F; Bats AS
Int J Gynecol Cancer; 2017 Jun; 27(5):953-960. PubMed ID: 28525912
[TBL] [Abstract][Full Text] [Related]
27. Differential Expression and Clinical Significance of DNA Methyltransferase 3B (DNMT3B), Phosphatase and Tensin Homolog (PTEN) and Human MutL Homologs 1 (hMLH1) in Endometrial Carcinomas.
Li W; Wang Y; Fang X; Zhou M; Li Y; Dong Y; Wang R
Med Sci Monit; 2017 Feb; 23():938-947. PubMed ID: 28220037
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers.
Kobayashi Y; Nakamura K; Nomura H; Banno K; Irie H; Adachi M; Iida M; Umene K; Nogami Y; Masuda K; Kisu I; Ueki A; Yamagami W; Kataoka F; Hirasawa A; Tominaga E; Susumu N; Aoki D
Int J Gynecol Cancer; 2015 Mar; 25(3):440-6. PubMed ID: 25695547
[TBL] [Abstract][Full Text] [Related]
29. Variable MLH1 promoter methylation patterns in endometrial carcinomas of endometrioid subtype lacking DNA mismatch repair.
Helmle KE; Otto CJ; Constantinescu G; Honore LH; Andrew SE
Int J Gynecol Cancer; 2005; 15(6):1089-96. PubMed ID: 16343186
[TBL] [Abstract][Full Text] [Related]
30. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
32. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
33. Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.
van Weelden WJ; van der Putten LJM; Inda MA; van Brussel A; Snijders MPLM; Schriever LMM; Bulten J; Massuger LFAG; van de Stolpe A; Pijnenborg JMA
Br J Cancer; 2020 Sep; 123(5):785-792. PubMed ID: 32507853
[TBL] [Abstract][Full Text] [Related]
34. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas.
de Jong RA; Boerma A; Boezen HM; Mourits MJ; Hollema H; Nijman HW
Int J Cancer; 2012 Oct; 131(8):1828-36. PubMed ID: 22287095
[TBL] [Abstract][Full Text] [Related]
35. Stromal Clues in Endometrial Carcinoma: Loss of Expression of β-Catenin, Epithelial-Mesenchymal Transition Regulators, and Estrogen-Progesterone Receptor.
Senol S; Sayar I; Ceyran AB; Ibiloglu I; Akalin I; Firat U; Kosemetin D; Engin Zerk P; Aydin A
Int J Gynecol Pathol; 2016 May; 35(3):238-48. PubMed ID: 26367784
[TBL] [Abstract][Full Text] [Related]
36. Expression of selected molecular factors in two types of endometrial cancer.
Markowska A; Gryboś A; Marszałek A; Bednarek W; Filas V; Gryboś M; Markowska J; Mądry R; Więckowska B; Nowalińska D; Szarszewska M
Adv Clin Exp Med; 2021 Oct; 30(10):1057-1064. PubMed ID: 34510841
[TBL] [Abstract][Full Text] [Related]
37. Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.
Carcangiu ML; Radice P; Casalini P; Bertario L; Merola M; Sala P
Int J Surg Pathol; 2010 Feb; 18(1):21-6. PubMed ID: 19443869
[TBL] [Abstract][Full Text] [Related]
38. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
39. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
40. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
